COMP <GO>
ARWR vs CORT // FREE CASH FLOW YIELD
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Corcept Therapeutics Incorporated (NASDAQ) • 15-METRIC TALLY: ARWR 8
— CORT 3
▲ FREE CASH FLOW YIELD LEADER: ARWR
LAST: $59.57 (-0.55%) • MKT CAP: $8.46B
fcf-yield
1.84%
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
fcf-yield
1.53%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. CORT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | CORT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 4.80% | +6.30 | ARWR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 95.0x | -21.20 | ARWR | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.84% | 1.53% | +0.31 | ARWR | /fcf-yield <GO> |
| Operating Margin | 11.90% | 5.90% | +6.00 | ARWR | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 13.10% | -13.30 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 12.80% | +167.20 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 26.00 | -19.40 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.3 | 27.6 | +13.70 | ARWR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.88 | +0.08 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 78.3x | -60.30 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.46B | $8.77B | -$307.8M | CORT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | CORT REV | ARWR GROSS % | CORT GROSS % | ARWR FCF | CORT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $761.4M | — | 98.3% | $156.9M | $141.8M |
| FY 2024 | $3.6M | $675.0M | — | 98.4% | -$604.3M | $196.1M |
| FY 2023 | $240.7M | $482.4M | — | — | -$164.7M | $105.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
CORT // BETA 0.88